KLRS Q4 2021 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena

KLRSKalaris Therapeutics Inc

$187M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$554,000

Operating Income

-$56M

Net Income

-$58M

EPS (Diluted)

$-20.96

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$287M

Total Liabilities

$61M

Stockholders' Equity

$225M

Cash & Equivalents

$202M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$554,000	-$18,000	-2977.8%
Operating Income	-$56M	-$25M	-119.5%
Net Income	-$58M	-$25M	-129.9%